South Korea's Celltrion launched the domestic investor roadshow for a delayed W1 trillion $881 million initial public offering of its sales and distribution division on Monday, hoping to capitalise on robust investor sentiment towards biopharmaceutical IPOs.
Sources familiar with the situation said Celltrion Healthcare, which is headquartered in Incheon, has also begun to gauge interest from international investors ahead of an international roadshow starting July 3. Drugs group Celltrion aims to list the business on Kosdaq by August-end.
The start of the domestic investor roadshow marks an end to the recent saga surrounding Celltrion Healthcare's accounting practices. Celltrion Healthcare had intended to...
¬ Haymarket Media Limited. All rights reserved.
